Disease Attributes
8
0
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
Strategy to Avoid Excessive Oxygen in Major Burn Patients
Vorasidenib Expanded Access Program
Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical Admission
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed